Amgen (AMGN) attracts significant investor attention as a recognized growth stock with financial performance displaying strong
revenue increase. The stock was revised by
Mizuho and
UBS analysts who upped the stock price target following Q1 update while AMGN was downgraded by an analyst over future growth concerns.
Bayesian Capital Management,
Cartrust Financial Advisors,
CoreCap Advisors, and
Bridgefront Capital are growing their stock holdings. Unfortunately, shares of
Amgen were sold by
Axa S.A.,
Family Management Corp and
Caxton Associates LP. Following
Q1 earnings release, stock moves witnessed are of relevance. The
UK approval for
Amgen’s Tepezza for treatment in Thyroid Eye Disease is a significant development.
AMGN's key drugs,
Repatha, Evenity & Blincyto have been reported to drive Q1 sales growth. Interesting point to note is the increased interest from political figures, specifically
Rep. Marjorie Taylor Greene. AMGN is reportedly among the innovative healthcare stocks to watch in 2025.
Strategic expansion plans involving a $900M push in Ohio facilities are on the way which is expected to create 350 jobs
Amgen AMGN News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 10 May 2025 13:00:47 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 3
